MAP1LC3A and gastric cancer: LC3A globular/stone like expression patterns have been associated with tumour aggressiveness or poor prognosis in breast [33], endometrial [34], pulmonary carcinoma [35], cutaneous SCC [36], urothelial cell carcinoma (UCC) [37], colorectal cancer [38], glioblastoma [39] and gastric cancer [40] using an anti-LC3A antibody from Abgent (AP1805a).